Global Achondroplasia Treatment 麻豆原创 2025 by Company, Regions, Type and Application, Forecast to 2031

Publication ID:

GIR012510492

Publication Date:

January 27, 2025

Pages:

Publisher:

GIR

Countries:

Global [1]

USD 3,480.00

Specialty Chemicals [2]

Manufacturing (Chemicals) [3]

Chemicals [4]

Description:

The global Achondroplasia Treatment market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.
Achondroplasia is a disorder of bone growth that prevents the changing of cartilage (particularly in the long bones of the arms and legs) to bone. It is characterized by dwarfism, limited range of motion at the elbows, large head size (macrocephaly), small fingers, and normal intelligence. Achondroplasia (ACH) is a rare disease that causes short stature (adult height of approximately 130 cm for males and approximately 125 cm for females) with short limbs. There is no effective treatment available, and this disease is designated as an intractable disease by the Ministry of Health, Labour and Welfare. This disease results mainly from a genetic defect in FGFR3 (fibroblast growth factor type 3 receptor). This genetic change causes the receptor to be overly active to growth factors such as FGF2, which leads to reduced growth of chondrocytes, resulting a short stature. ACH occurs in a frequency of 1 in approximately 25,000 normal live births and is estimated to affect approximately 250,000 people worldwide.
The main global Achondroplasia Treatment players include Ascendis Pharma, BioMarin, Ribomic, QED Therapeutics, Pfizer, Astellas, etc. North America is the largest consumer market for Achondroplasia Treatment, accounting for about 46%, followed by Europe and China. In terms of type, CNP Analogue is the largest segment, with a share over 57%. And in terms of application, the largest application is Hospital, followed by Retail Pharmacy.
This report is a detailed and comprehensive analysis for global Achondroplasia Treatment market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Achondroplasia Treatment market size and forecasts, in consumption value ($ Million), 2020-2031
Global Achondroplasia Treatment market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Achondroplasia Treatment market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Achondroplasia Treatment market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Achondroplasia Treatment
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Achondroplasia Treatment market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Ascendis Pharma, BioMarin, Ribomic, QED Therapeutics, Pfizer, Astellas, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Achondroplasia Treatment market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
CNP Analogue
Ligand Trap
TKI
Others
麻豆原创 segment by Application
Hospital
Retail Pharmacy
Others
麻豆原创 segment by players, this report covers
Ascendis Pharma
BioMarin
Ribomic
QED Therapeutics
Pfizer
Astellas
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Achondroplasia Treatment product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Achondroplasia Treatment, with revenue, gross margin, and global market share of Achondroplasia Treatment from 2020 to 2025.
Chapter 3, the Achondroplasia Treatment competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Achondroplasia Treatment market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Achondroplasia Treatment.
Chapter 13, to describe Achondroplasia Treatment research findings and conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Achondroplasia Treatment by Type
1.3.1 Overview: Global Achondroplasia Treatment 麻豆原创 Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Achondroplasia Treatment Consumption Value 麻豆原创 Share by Type in 2024
1.3.3 CNP Analogue
1.3.4 Ligand Trap
1.3.5 TKI
1.3.6 Others
1.4 Global Achondroplasia Treatment 麻豆原创 by Application
1.4.1 Overview: Global Achondroplasia Treatment 麻豆原创 Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Hospital
1.4.3 Retail Pharmacy
1.4.4 Others
1.5 Global Achondroplasia Treatment 麻豆原创 Size & Forecast
1.6 Global Achondroplasia Treatment 麻豆原创 Size and Forecast by Region
1.6.1 Global Achondroplasia Treatment 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Achondroplasia Treatment 麻豆原创 Size by Region, (2020-2031)
1.6.3 North America Achondroplasia Treatment 麻豆原创 Size and Prospect (2020-2031)
1.6.4 Europe Achondroplasia Treatment 麻豆原创 Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Achondroplasia Treatment 麻豆原创 Size and Prospect (2020-2031)
1.6.6 South America Achondroplasia Treatment 麻豆原创 Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Achondroplasia Treatment 麻豆原创 Size and Prospect (2020-2031)
2 Company Profiles
2.1 Ascendis Pharma
2.1.1 Ascendis Pharma Details
2.1.2 Ascendis Pharma Major Business
2.1.3 Ascendis Pharma Achondroplasia Treatment Product and Solutions
2.1.4 Ascendis Pharma Achondroplasia Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Ascendis Pharma Recent Developments and Future Plans
2.2 BioMarin
2.2.1 BioMarin Details
2.2.2 BioMarin Major Business
2.2.3 BioMarin Achondroplasia Treatment Product and Solutions
2.2.4 BioMarin Achondroplasia Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 BioMarin Recent Developments and Future Plans
2.3 Ribomic
2.3.1 Ribomic Details
2.3.2 Ribomic Major Business
2.3.3 Ribomic Achondroplasia Treatment Product and Solutions
2.3.4 Ribomic Achondroplasia Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Ribomic Recent Developments and Future Plans
2.4 QED Therapeutics
2.4.1 QED Therapeutics Details
2.4.2 QED Therapeutics Major Business
2.4.3 QED Therapeutics Achondroplasia Treatment Product and Solutions
2.4.4 QED Therapeutics Achondroplasia Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 QED Therapeutics Recent Developments and Future Plans
2.5 Pfizer
2.5.1 Pfizer Details
2.5.2 Pfizer Major Business
2.5.3 Pfizer Achondroplasia Treatment Product and Solutions
2.5.4 Pfizer Achondroplasia Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Pfizer Recent Developments and Future Plans
2.6 Astellas
2.6.1 Astellas Details
2.6.2 Astellas Major Business
2.6.3 Astellas Achondroplasia Treatment Product and Solutions
2.6.4 Astellas Achondroplasia Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Astellas Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Achondroplasia Treatment Revenue and Share by Players (2020-2025)
3.2 麻豆原创 Share Analysis (2024)
3.2.1 麻豆原创 Share of Achondroplasia Treatment by Company Revenue
3.2.2 Top 3 Achondroplasia Treatment Players 麻豆原创 Share in 2024
3.2.3 Top 6 Achondroplasia Treatment Players 麻豆原创 Share in 2024
3.3 Achondroplasia Treatment 麻豆原创: Overall Company Footprint Analysis
3.3.1 Achondroplasia Treatment 麻豆原创: Region Footprint
3.3.2 Achondroplasia Treatment 麻豆原创: Company Product Type Footprint
3.3.3 Achondroplasia Treatment 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Achondroplasia Treatment Consumption Value and 麻豆原创 Share by Type (2020-2025)
4.2 Global Achondroplasia Treatment 麻豆原创 Forecast by Type (2026-2031)
5 麻豆原创 Size Segment by Application
5.1 Global Achondroplasia Treatment Consumption Value 麻豆原创 Share by Application (2020-2025)
5.2 Global Achondroplasia Treatment 麻豆原创 Forecast by Application (2026-2031)
6 North America
6.1 North America Achondroplasia Treatment Consumption Value by Type (2020-2031)
6.2 North America Achondroplasia Treatment 麻豆原创 Size by Application (2020-2031)
6.3 North America Achondroplasia Treatment 麻豆原创 Size by Country
6.3.1 North America Achondroplasia Treatment Consumption Value by Country (2020-2031)
6.3.2 United States Achondroplasia Treatment 麻豆原创 Size and Forecast (2020-2031)
6.3.3 Canada Achondroplasia Treatment 麻豆原创 Size and Forecast (2020-2031)
6.3.4 Mexico Achondroplasia Treatment 麻豆原创 Size and Forecast (2020-2031)
7 Europe
7.1 Europe Achondroplasia Treatment Consumption Value by Type (2020-2031)
7.2 Europe Achondroplasia Treatment Consumption Value by Application (2020-2031)
7.3 Europe Achondroplasia Treatment 麻豆原创 Size by Country
7.3.1 Europe Achondroplasia Treatment Consumption Value by Country (2020-2031)
7.3.2 Germany Achondroplasia Treatment 麻豆原创 Size and Forecast (2020-2031)
7.3.3 France Achondroplasia Treatment 麻豆原创 Size and Forecast (2020-2031)
7.3.4 United Kingdom Achondroplasia Treatment 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Russia Achondroplasia Treatment 麻豆原创 Size and Forecast (2020-2031)
7.3.6 Italy Achondroplasia Treatment 麻豆原创 Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific Achondroplasia Treatment Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Achondroplasia Treatment Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Achondroplasia Treatment 麻豆原创 Size by Region
8.3.1 Asia-Pacific Achondroplasia Treatment Consumption Value by Region (2020-2031)
8.3.2 China Achondroplasia Treatment 麻豆原创 Size and Forecast (2020-2031)
8.3.3 Japan Achondroplasia Treatment 麻豆原创 Size and Forecast (2020-2031)
8.3.4 South Korea Achondroplasia Treatment 麻豆原创 Size and Forecast (2020-2031)
8.3.5 India Achondroplasia Treatment 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Southeast Asia Achondroplasia Treatment 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Australia Achondroplasia Treatment 麻豆原创 Size and Forecast (2020-2031)
9 South America
9.1 South America Achondroplasia Treatment Consumption Value by Type (2020-2031)
9.2 South America Achondroplasia Treatment Consumption Value by Application (2020-2031)
9.3 South America Achondroplasia Treatment 麻豆原创 Size by Country
9.3.1 South America Achondroplasia Treatment Consumption Value by Country (2020-2031)
9.3.2 Brazil Achondroplasia Treatment 麻豆原创 Size and Forecast (2020-2031)
9.3.3 Argentina Achondroplasia Treatment 麻豆原创 Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa Achondroplasia Treatment Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Achondroplasia Treatment Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Achondroplasia Treatment 麻豆原创 Size by Country
10.3.1 Middle East & Africa Achondroplasia Treatment Consumption Value by Country (2020-2031)
10.3.2 Turkey Achondroplasia Treatment 麻豆原创 Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Achondroplasia Treatment 麻豆原创 Size and Forecast (2020-2031)
10.3.4 UAE Achondroplasia Treatment 麻豆原创 Size and Forecast (2020-2031)
11 麻豆原创 Dynamics
11.1 Achondroplasia Treatment 麻豆原创 Drivers
11.2 Achondroplasia Treatment 麻豆原创 Restraints
11.3 Achondroplasia Treatment Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Achondroplasia Treatment Industry Chain
12.2 Achondroplasia Treatment Upstream Analysis
12.3 Achondroplasia Treatment Midstream Analysis
12.4 Achondroplasia Treatment Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

Companies Mentioned:

Ascendis Pharma
BioMarin
Ribomic
QED Therapeutics
Pfizer
Astellas

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.